Combination treatment shows promise in BRCA-, PALB2-mutated breast cancer
SAN ANTONIO — Combining a poly(ADP-ribose) polymerase inhibitor with a PD-1 antibody in a nonchemotherapy regimen for BRCA-mutated breast cancer showed promise, according to a presenter here.
Erica L. Mayer, MD, MPH, a medical oncologist from Dana-Farber Cancer Institute, presented the ER-positive cohort of the phase 2 prospective study during a rapid-fire session at the San Antonio Breast Cancer Symposium. The other two arms of the study will include triple-negative breast cancer.
The trial includes BRCA1, BRCA2 and PALB2 mutations treated with the regimen prior to surgery.
Three of the patients, or 16.7%, achieved a pathologic complete response with 18 weeks of nonchemotherapy, targeted treatment. Additionally, 44.4% achieved a residual cancer burden of zero or one, which is a near pathologic complete response, Mayer said.
“We feel excited with these results because this is, again, a nonchemotherapy approach,” Mayer said. “We’re all very interested in how we can find nonchemotherapy and immunology-based approaches that can best treat this subtype of breast cancer.”
Collapse
Mayer E. Abstract RF3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
